Cilnidipine Treatment for Mild-to-moderate Essential Hypertension

Objective To evaluate the efficacy and safety of domestic produced cilnidipine in patients with mild-to-moderate essential hypertension. Methods Patients (n=234) were randomly assigned to receive cilnidipine (5 mg/d)or amlodipine(5 mg/d) for 8 weeks. The dosage was double when DBP was sustained ≥90 mm Hg or the magnitude of reduction of DBP was less than 10 mm Hg. Results SBP/DBP was decreased significantly for(17.9±10.0)/(14.9±5.3) mm Hg and(19.6±9.6)/(14.9±6.3)mm Hg in cilnidipine group and amlodipine group respectively. Response rate was 92.5% in cilnidipine group, and 87.2% in amlodipine group with no changes in heart rate. Adverse reactions were slight, such as headache, flushing, hectic fever, edema of lower extremities. The T/P ratio of cilnidipine were 0.69 for SBP and 0.65 for DBP. Conclusion cilnidipine was proved to be a stable, safe and effective antihypertensive medication analogus to amlodipine with little adverse reactions.